Vigilant Capital Management LLC acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN) during the fourth quarter, Holdings Channel reports. The institutional investor acquired 24,909 shares of the life sciences company’s stock, valued at approximately $8,263,000.
Other institutional investors also recently bought and sold shares of the company. Kornitzer Capital Management Inc. KS grew its stake in Illumina by 20.4% during the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 104,845 shares of the life sciences company’s stock worth $31,896,000 after purchasing an additional 17,796 shares in the last quarter. Integrated Wealth Concepts LLC lifted its stake in Illumina by 23.4% in the third quarter. Integrated Wealth Concepts LLC now owns 1,278 shares of the life sciences company’s stock worth $389,000 after acquiring an additional 242 shares during the last quarter. Sterling Investment Advisors Ltd. grew its holdings in Illumina by 14.6% during the 3rd quarter. Sterling Investment Advisors Ltd. now owns 2,165 shares of the life sciences company’s stock worth $659,000 after acquiring an additional 275 shares in the last quarter. Keudell Morrison Wealth Management acquired a new position in Illumina during the 2nd quarter worth approximately $1,483,000. Finally, Sunbelt Securities Inc. grew its holdings in Illumina by 130.9% during the 3rd quarter. Sunbelt Securities Inc. now owns 1,443 shares of the life sciences company’s stock worth $438,000 after acquiring an additional 818 shares in the last quarter. 91.75% of the stock is currently owned by institutional investors and hedge funds.
A number of equities research analysts have recently weighed in on the stock. Argus raised their price objective on shares of Illumina from $300.00 to $340.00 and gave the company a “buy” rating in a report on Wednesday, September 25th. BidaskClub raised Illumina from a “buy” rating to a “strong-buy” rating in a report on Wednesday, December 11th. Citigroup started coverage on Illumina in a research note on Monday, January 6th. They issued a “buy” rating and a $385.00 price target on the stock. Wells Fargo & Co started coverage on Illumina in a report on Tuesday, January 7th. They set an “underweight” rating and a $300.00 price target for the company. Finally, Cowen reaffirmed an “outperform” rating and set a $335.00 price objective (up from $320.00) on shares of Illumina in a research report on Wednesday, December 18th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $340.69.
In other Illumina news, SVP Phillip G. Febbo sold 155 shares of Illumina stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $300.00, for a total value of $46,500.00. Following the transaction, the senior vice president now directly owns 1,506 shares in the company, valued at $451,800. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Charles Dadswell sold 193 shares of the company’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $297.28, for a total transaction of $57,375.04. Following the completion of the sale, the senior vice president now directly owns 5,069 shares of the company’s stock, valued at $1,506,912.32. The disclosure for this sale can be found here. In the last quarter, insiders sold 3,920 shares of company stock valued at $1,262,212. 0.38% of the stock is owned by company insiders.
Shares of ILMN traded down $1.07 during midday trading on Friday, reaching $324.89. 48,738 shares of the stock were exchanged, compared to its average volume of 1,145,269. The business’s 50-day moving average price is $326.84 and its 200 day moving average price is $309.67. The company has a debt-to-equity ratio of 0.41, a current ratio of 6.82 and a quick ratio of 6.15. Illumina, Inc. has a twelve month low of $263.30 and a twelve month high of $380.76. The company has a market capitalization of $47.62 billion, a price-to-earnings ratio of 56.74, a PEG ratio of 2.18 and a beta of 1.05.
Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, October 24th. The life sciences company reported $1.93 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.53. The firm had revenue of $907.00 million during the quarter, compared to analysts’ expectations of $872.65 million. Illumina had a return on equity of 22.05% and a net margin of 28.14%. The business’s revenue was up 6.3% on a year-over-year basis. During the same period in the prior year, the firm earned $1.52 EPS. As a group, equities research analysts expect that Illumina, Inc. will post 6.46 earnings per share for the current fiscal year.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Read More: What is a back-end load?
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.